Document is current
Any future updates will be listed below
-
Authors
Dekkers, Koen F. https://orcid.org/0000-0002-4074-7235
Pertiwi, Kamalita https://orcid.org/0000-0003-2861-9051
Baldanzi, Gabriel https://orcid.org/0000-0003-3962-3953
Lundmark, Per https://orcid.org/0009-0006-2334-8802
Hammar, Ulf
Moksnes, Marta Riise https://orcid.org/0000-0002-2690-5153
Coward, Eivind https://orcid.org/0009-0008-1323-3555
Nethander, Maria https://orcid.org/0000-0003-3688-906X
Salih, Ghassan Ali https://orcid.org/0009-0003-5938-8222
Miari, Mariam
Nguyen, Diem https://orcid.org/0000-0002-9680-5772
Sayols-Baixeras, Sergi
Eklund, Aron C. https://orcid.org/0000-0003-0861-1001
Holm, Jacob Bak https://orcid.org/0000-0003-1756-0875
Nielsen, H. Bjørn https://orcid.org/0000-0003-2281-5713
Volpiano, Camila Gazolla
Méric, Guillaume https://orcid.org/0000-0001-6288-9958
Thangam, Manonanthini https://orcid.org/0000-0002-7164-6525
Hakaste, Liisa
Tuomi, Tiinamaija
Ahlqvist, Emma https://orcid.org/0000-0002-6513-2384
Smith, Christopher A.
Allen, Marie
Reimann, Frank https://orcid.org/0000-0001-9399-6377
Gribble, Fiona M. https://orcid.org/0000-0002-4232-2898
Ohlsson, Claes https://orcid.org/0000-0002-9633-2805
Hveem, Kristian
Melander, Olle
Nilsson, Peter M. https://orcid.org/0000-0002-5652-8459
Engström, Gunnar
Smith, J. Gustav
Michaëlsson, Karl
Ärnlöv, Johan
Orho-Melander, Marju https://orcid.org/0000-0002-3578-2503
Fall, Tove https://orcid.org/0000-0003-2071-5866
- License Information
-
More Information
Article History
Received: 28 August 2024
Accepted: 14 January 2026
First Online: 13 February 2026
Competing interests
: The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. A.C.E., J.B.H. and H.B.N. are employees of Cmbio. J.Ä. has served on the advisory boards for Astella, AstraZeneca and Boehringer Ingelheim and has received lecturing fees from AstraZeneca, Boehringer Ingelheim and Novartis, all unrelated to the present work. P.M.N. has received lecture fees from Novartis, Novo Nordisk, Amgen and Boehringer Ingelheim. F.M.G. and F.R. received grant funding from Eli Lilly and AstraZeneca for other projects. C.O. is an applicant on filed patent applications on the effect of probiotics on bone metabolism. The other authors declare no competing interests.
